Cyclin Dependent Kinase Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Cyclin Dependent Kinase Inhibitor is a class of proteins produced by the immune system that play a critical role in regulating the body's response to infections, tumors, and other diseases. It exerts its therapeutic effects by modulating immune responses, inhibiting viral replication, and enhancing anti-tumor activity. Cyclin Dependent Kinase Inhibitor finds application in various disease indications, including chronic viral infections such as hepatitis B and C, certain types of cancer like melanoma and leukemia, autoimmune disorders such as multiple sclerosis, and rare genetic diseases like hairy cell leukemia. According to the World Health Organization (WHO), hepatitis C affects an estimated 2.8 million people in Europe and around 2.7 million people in the United States. In the case of multiple sclerosis, Europe has one of the highest prevalence rates globally, with approximately 700,000 people affected. The American Cancer Society reports that melanoma, a type of skin cancer, accounts for about 1% of all skin cancers but causes the majority of skin cancer deaths. Leukemia, on the other hand, affects around 28,000 adults and more than 3,000 children in the United States each year.

Growth drivers of the Cyclin-Dependent Kinase Inhibitor market include increasing awareness about its therapeutic benefits, ongoing research and development activities focusing on new formulations and delivery methods, and collaborations between pharmaceutical companies and healthcare providers. Companies such as Pfizer, Eli Lilly, Novartis, Sumitomo Pharma, Jiangsu Hengrui Pharma, G1 Therap, Ligand, Merck (Msd), Piramal Phytocare, and AstraZeneca cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Eisai is currently conducting a clinical trial of the drug E7070 for the treatment of acute myelocytic leukemia.

Key Developments

• In May 2023, Novartis Pharmaceuticals completed a phase II RIGHT Choice trial of Kisqali for Breast cancer in Egypt, India, Jordan, Lebanon, Russian Federation, Saudi Arabia, Singapore, South Africa, Thailand, Turkey, Taiwan, Malaysia, Vietnam
• In June 2023, G1 therapeutics presented adverse events data of Cosela from a phase II trial of Triple-negative breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

Approved Cyclin-Dependent Kinase Inhibitor molecules

• Ibrance (palbociclib)
• Verzenio (abemaciclib)
• Kisqali (ribociclib)

Cyclin Dependent Kinase Inhibitor Pipeline Molecules

• Alvocidib (DSP-2033)
• Dinaciclib (MK-7965)
• Riviciclib (P27600)
• TQB3616
• Indisulam (E7070)
• Lerociclib (G1T38)
• Roniciclib (BAY1000394)
• Seliciclib (CYC202)
• Zotiraciclib (TG02)
• Fadraciclib (CYC065)
• Milciclib (TZLS-201)

Clinical Activity and Development of Cyclin-Dependent Kinase Inhibitor

In the Cyclin-Dependent Kinase Inhibitor space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,

• In June 2023, Medsir released efficacy data from a phase II trial of Iburance in breast cancer.
• In June 2023, Pfizer initiated Phase-III clinical trials of Iburance in HER2-negative-breast-cancer (Combination therapy, First-line therapy, Metastatic disease, Recurrent) in the USA.